Submissions from 2023
Purposivist Reasoning in Federal Civil Procedure, Lumen N. Mulligan and Emily Pennington
Book Review: The Walled Garden: Law and Privacy in Modern Society, Ariel Newman
Restoring Confidence in Educational Technologies, Ariel Newman
Book Review: Critical Race Judgments: Rewritten U.S. Court Opinions on Race and the Law, Julia M. Pluta
Real Property Issues in Family Law: An Annotated Bibliography, Allen Rostron
Constitutional Issues in Family Law: An Annotated Bibliography (Part 2 of 2), Allen K. Rostron
Inclusiveness: Advancing Environmental Justice in a Diverse Democracy, Irma S. Russell and Alexandra D. Dunn
IR triumphs of 2023, Christina M. Sautter and Sergio Alberto Gramitto Ricci
Legal Education and NextGen: Recommendations for Transitioning to a New Assessment Model, Wanda Temm
Antibody Patents: Use of the Written Description and Enablement Requirements at the Patent & Trademark Office, S. Sean Tu and Christopher M. Holman
Empirical Study of the Role of the Chinese Guiding Case System in Chinese Law, Dong Yan and Jeffrey E. Thomas
Advance Care Planning is Critical to Overall Wellbeing, Barbara Zabawa
Submissions from 2022
Covid-19: A Catalyst to Automate Protection Order Petitions to Support Self-Represented Litigants, Ayyoub Ajmi
Cross-Examination Content and the "Power of Not", Patrick C. Brayer
The Instrumental Case for Corporate Diversity, Naomi Cahn, June Carbone, and Nancy Levit
Name, Image, and Likeness in Amateur Sports, Kenneth D. Ferguson
The Corporate Forum, Sergio Alberto Gramitto Ricci and Christina M. Sautter
The Educated Retail Investor: A Response to "Regulating Democratized Investing", Sergio Alberto Gramitto Ricci and Christina M. Sautter
The Wireless Investors Movement, Sergio Alberto Gramitto Ricci and Christina M. Sautter
A Look at the Current Status of the CRISPR Patent Interferences Involving Broad Institute, University of California and University of Vienna, ToolGen, and Sigma-Aldrich, Christopher M. Holman
Amgen v. Sanofi: The Supreme Court Takes up the Enablement Requirement in the Context of Therapeutic Monoclonal Antibodies, Christopher M. Holman
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part I, Christopher M. Holman
Is the Chemical Genus Claim Really “Dead” at the Federal Circuit?: Part II, Christopher M. Holman
The Broad Institute Scores Another Victory in Its Battle with the University of California over the Patenting of CRIPSR, Christopher M. Holman
The Enablement and Written Description Requirements Through the Lens of the Federal Circuit's Actions (As Opposed to Its Words), Christopher M. Holman